Audit of acute Charcot’s disease in the UK: the CDUK study

作者: F. L. Game , R. Catlow , G. R. Jones , M. E. Edmonds , E. B. Jude

DOI: 10.1007/S00125-011-2354-7

关键词:

摘要: Aims/hypothesis We studied factors associated with the development and resolution of acute Charcot foot using a web-based observational study. Methods Clinicians managing cases in UK Ireland between June 2005 February 2007 were invited to register anonymised details on secure website. Results A total 288 (age 57.0±11.3 years [mean±SD]; 71.2% male) registered from 76 centres. Of these, 36% patients recalled an episode relevant trauma preceding 6 months, while 12% had surgery affected foot. In 101 (35%) cases, ulceration was present at registration 20% these osteomyelitis. Non-removable off-loading devices used presentation 35.4% removable 50%. Data available for 219 patients. The median time 9 months whose initial management included use non-removable off-loading, compared 12 remainder (p=0.001). Bisphosphonates administered intravenously 25.4% orally 19.4% cases. who received bisphosphonates longer than those did not (10 p=0.005). Conclusions/interpretation earlier series. Although limited by being non-randomised, data suggest that may shorten resolution. They provide no evidence indicate is beneficial.

参考文章(15)
Kozak Gp, Frykberg Rg, Neuropathic arthropathy in the diabetic foot. American Family Physician. ,vol. 17, pp. 105- 113 ,(1978)
David R. Sinacore, Acute Charcot arthropathy in patients with diabetes mellitus: healing times by foot location. Journal of Diabetes and Its Complications. ,vol. 12, pp. 287- 293 ,(1998) , 10.1016/S1056-8727(98)00006-3
Michael S. Pinzur, Tammy Lio, Matthew Posner, Treatment of Eichenholtz Stage I Charcot Foot Arthropathy with a Weightbearing Total Contact Cast Foot & Ankle International. ,vol. 27, pp. 324- 329 ,(2006) , 10.1177/107110070602700503
D. Pitocco, V. Ruotolo, S. Caputo, L. Mancini, C. M. Collina, A. Manto, P. Caradonna, G. Ghirlanda, Six-Month Treatment With Alendronate in Acute Charcot Neuroarthropathy: A randomized controlled trial Diabetes Care. ,vol. 28, pp. 1214- 1215 ,(2005) , 10.2337/DIACARE.28.5.1214
D. Pitocco, G. Zelano, G. Gioffre, E. Di Stasio, F. Zaccardi, F. Martini, T. Musella, G. Scavone, M. Galli, S. Caputo, L. Mancini, G. Ghirlanda, Association Between Osteoprotegerin G1181C and T245G Polymorphisms and Diabetic Charcot Neuroarthropathy A case-control study Diabetes Care. ,vol. 32, pp. 1694- 1697 ,(2009) , 10.2337/DC09-0243
P.L. Selby, M.J. Young, A.J.M. Boulton, Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy? Diabetic Medicine. ,vol. 11, pp. 28- 31 ,(1994) , 10.1111/J.1464-5491.1994.TB00225.X
Rajbhandari S., Jenkins R., Davies C., Tesfaye S., Charcot neuroarthropathy in diabetes mellitus. Diabetologia. ,vol. 45, pp. 1085- 1096 ,(2002) , 10.1007/S00125-002-0885-7
T.-K. Pakarinen, H.-J. Laine, H. Maenpaa, P. Mattila, J. Lahtela, The Effect of Zoledronic Acid on the Clinical Resolution of Charcot Neuroarthropathy: A pilot randomized controlled trial Diabetes Care. ,vol. 34, pp. 1514- 1516 ,(2011) , 10.2337/DC11-0396
E. B. Jude, P. L. Selby, J. Burgess, P. Lilleystone, E. B. Mawer, S. R. Page, M. Donohoe, A. V. M. Foster, M. E. Edmonds, A. J. M. Boulton, Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. ,vol. 44, pp. 2032- 2037 ,(2001) , 10.1007/S001250100008
W. Jeffcoate, J. Lima, L. Nobrega, The Charcot foot. Diabetic Medicine. ,vol. 17, pp. 253- 258 ,(2000) , 10.1046/J.1464-5491.2000.00233.X